20 June 2013
Keywords: strong, early, data, davanat, plus, 5-fu, crc
Article | 10 March 2008
The USA's Pro-Pharmaceuticals says that data from all end-stage colorectal cancer patients in a Phase II trial showed that its
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 March 2008
3 March 2008
19 June 2013
© 2013 thepharmaletter.com